[Autoantibodies in systemic sclerosis]

Area of Science:

• Immunology
• Rheumatology
• Autoimmunity

Background:

• Systemic sclerosis (SSc) is a rare, progressive fibrotic connective tissue disorder.
• Classical autoantibodies include anti-topoisomerase I (ATA) and anti-centromere (ACA).
• Emerging autoantibodies against antigens like RNA polymerase III and Ku are recognized.

Purpose of the Study:

• To review the current knowledge on the clinical significance of autoantibodies in systemic sclerosis.
• To highlight the diagnostic importance of autoantibodies in SSc.
• To explore correlations between specific autoantibodies and clinical features.

Main Methods:

• Literature review of studies on autoantibodies in systemic sclerosis.
• Analysis of clinical correlations associated with various autoantibodies.
• Examination of the role of autoantibodies in diagnostic criteria.

Main Results:

• Established autoantibodies (ATA, ACA) are key diagnostic markers.
• Newer autoantibodies (anti-RNA polymerase III, anti-Ku) show specific clinical associations (e.g., renal crisis, myositis).
• Autoantibodies are integral to the ACR/EULAR 2013 classification criteria for SSc.

Conclusions:

• Autoantibodies play a vital role in diagnosing and understanding systemic sclerosis.
• Specific autoantibodies correlate with distinct clinical phenotypes, aiding in patient management.
• Continued research into autoantibody significance is essential for advancing SSc care.